Estamos no ar no ! Saiba mais

AngioDynamics

ANGO

Valor de mercado US$ 473 mi

11,24 USD

-0,34

2,94%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

11,15

-0,09

0,8%

1 dia

-2,94%

5 dias

-1,58%

1 mês

-27,3%

3 meses

-20,51%

6 meses

7,46%

No acumulado do ano

-11,36%

1 ano

-4,1%

5 anos

-58,72%

10 anos

-33,69%

Sobre: AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.

Funcionários: 632

Saúde Instrumentos e suprimentos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 16,7%

Neutro 61,1%

Negativo 22,2%

AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist

AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrenched competitors and unpredictable clinician adoption, especially for NanoKnife. Recent results showed strong Med Tech growth and margin improvement, but higher-than-expected operating expenses and NanoKnife volatility spooked investors.

AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec.

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

Zacks Investment Research

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics Stock Is Falling Thursday: What's Going On?

AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results.

AngioDynamics Stock Is Falling Thursday: What's Going On?

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

The Motley Fool

Why AngioDynamics Crashed Today

AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.

Why AngioDynamics Crashed Today

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announced that Eric Honroth will become president and chief executive officer effective Nov. 2.

AngioDynamics Q1 Earnings Call Highlights

Zacks Investment Research

AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.

AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 2027 First Quarter Financial Highlights Quarter Ended August 31, 2026 YoY Growth Net Sales $80.9 million.

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026. Mr. Honroth will succeed Jim Clemmer, who will depart the Board on N.

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™